Article

Targeting GFPT2 to reinvigorate immunotherapy in EGFR-mutated NSCLC

2024-03-04

Abstract excerpt

In the evolving field of cancer immunotherapy, EGFR-mutated NSCLC presents a significant challenge, demonstrating marked innate resistance to established treatments. An effective method to counter this resistance remains elusive. Through comprehensive genetic and pharmacological analyses across various models, we have identified glutamine fructose-6-phosphate transaminase 2 (GFPT2) as a key facilitator of immune e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b5e3ba79-8501-5a12-a0e7-5829d2ef6c16
DOI: 10.1101/2024.03.01.582888

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting GFPT2 to reinvigorate immunotherapy in EGFR-mutated NSCLCDOI 10.1101/2024.03.01.582888Read

GFPT2 controls immune evasion in EGFR-mutated non-small cell lung cancerSemantic proximity Read

Cancer‐associated fibroblast expression of glutamine fructose‐6‐phosphate aminotransferase 2 ( GFPT2 ) is a prognostic marker in gastric cancerSemantic proximity Read

Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth.Semantic proximity Read

Integrated proteomic and glycoproteomic analysis reveals heterogeneity and molecular signatures of brain metastases from lung adenocarcinomas.Semantic proximity Read

Roles of GFPT2 Expression Levels On the Prognosis and Tumor Microenvironment of Colon CancerSemantic proximity Read

Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancerSemantic proximity Read

A non-canonical glucose metabolic rewiring enables resistance to cancer targeted therapySemantic proximity Read

TGM2-TUFM promotes acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC through p62-mediated lipophagy.Semantic proximity Read

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.Semantic proximity Read

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer.Semantic proximity Read

Hypoxia, Autophagy and Immune Escape in the Tumor Microenvironment: From Mechanisms to Therapeutic TargetingSemantic proximity Read

NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence via the induction of ASCT2Semantic proximity Read